Prognosis

Obesity Drug Firms Battle Over Price Versus Quality

An Eli Lilly & Co. Zepbound injection pen.
Photographer: Shelby Knowles/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Madison Muller

September 18, 2024 at 10:00 AM UTC

Good morning! It’s Madison in New York. The debate over compounded weight-loss drugs has made it to print. But first...

A few months ago, Eli Lilly & Co. — the world’s most valuable drugmaker — ran a full-page ad in the Wall Street Journal and other publications taking aim at the booming market for knockoff weight-loss drugs.